Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro
Authors
Keywords
-
Journal
Pharmaceutics
Volume 13, Issue 9, Pages 1400
Publisher
MDPI AG
Online
2021-09-07
DOI
10.3390/pharmaceutics13091400
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review
- (2021) Beatriz Oda Plasencia-García et al. PSYCHOPHARMACOLOGY
- New variant of SARS-CoV-2 in UK causes surge of COVID-19
- (2021) Tony Kirby Lancet Respiratory Medicine
- Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition
- (2021) Malavika Deodhar et al. Pharmaceutics
- Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitro
- (2021) Sebastian Schloer et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor
- (2021) Rita Humeniuk et al. CLINICAL PHARMACOKINETICS
- Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
- (2021) Nicholas G. Davies et al. NATURE
- Disease-drug and drug-drug interaction in COVID-19: Risk and assessment
- (2021) Devendra Kumar et al. BIOMEDICINE & PHARMACOTHERAPY
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
- (2020) Dawei Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia
- (2020) Ning Tang et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Reducing mortality from 2019-nCoV: host-directed therapies should be an option
- (2020) Alimuddin Zumla et al. LANCET
- Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
- (2020) Dominic Wichmann et al. ANNALS OF INTERNAL MEDICINE
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies
- (2020) Chunyan Yi et al. Cellular & Molecular Immunology
- What do we know about remdesivir drug interactions?
- (2020) Katherine Yang CTS-Clinical and Translational Science
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
- (2020) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The many estimates of the COVID-19 case fatality rate
- (2020) Dimple D Rajgor et al. LANCET INFECTIOUS DISEASES
- Real estimates of mortality following COVID-19 infection
- (2020) David Baud et al. LANCET INFECTIOUS DISEASES
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
- (2020) Xiuyuan Ou et al. Nature Communications
- Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19
- (2020) Massimo Tempestilli et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
- (2020) Brandi N. Williamson et al. NATURE
- Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection
- (2020) Sebastian Schloer et al. Viruses-Basel
- Potential Antiviral Options against SARS-CoV-2 Infection
- (2020) Aleksandr Ianevski et al. Viruses-Basel
- Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
- (2020) Victoria C. Yan et al. ACS Medicinal Chemistry Letters
- Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
- (2020) Andrea J. Pruijssers et al. Cell Reports
- Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice
- (2020) Maki Kiso et al. Communications Biology
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus
- (2020) Zeineb Mhamdi et al. Microorganisms
- Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis
- (2019) Niels C Pedersen et al. JOURNAL OF FELINE MEDICINE AND SURGERY
- Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer
- (2019) Alina Malyutina et al. PLoS Computational Biology
- Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
- (2019) Ariane J. Brown et al. ANTIVIRAL RESEARCH
- Coronaviren als Ursache respiratorischer Infektionen
- (2019) V. M. Corman et al. INTERNIST
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
- (2018) Maria L. Agostini et al. mBio
- Drug repurposing: progress, challenges and recommendations
- (2018) Sudeep Pushpakom et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
- (2017) Dustin Siegel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
- (2017) Timothy P. Sheahan et al. Science Translational Medicine
- GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo- and Paramyxoviruses
- (2017) Michael K. Lo et al. Scientific Reports
- Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
- (2016) Alimuddin Zumla et al. LANCET INFECTIOUS DISEASES
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
- (2016) Travis K. Warren et al. NATURE
- Serum fluoxetine and norfluoxetine levels support the safety of fluoxetine in overdose
- (2016) Stephanie Pope et al. Annals of General Psychiatry
- Entry inhibitors: New advances in HCV treatment
- (2016) Xi-Jing Qian et al. Emerging Microbes & Infections
- Metabolism and Pharmacokinetics of the Anti-Hepatitis C Virus Nucleotide Prodrug GS-6620
- (2014) Eisuke Murakami et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fluoxetine- and Norfluoxetine-Mediated Complex Drug–Drug Interactions: In Vitro to In Vivo Correlation of Effects on CYP2D6, CYP2C19, and CYP3A4
- (2014) J E Sager et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options
- (2014) Alimuddin Zumla et al. LANCET INFECTIOUS DISEASES
- Combinatorial Approaches to the Prevention and Treatment of HIV-1 Infection
- (2011) Vanessa Pirrone et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Drug resistance in HIV-1
- (2011) Daniel R Kuritzkes Current Opinion in Virology
- Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A Novel Pharmacological Group of Drugs with Broad Clinical Applications
- (2010) Johannes Kornhuber et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Antiviral Drug Resistance: Mechanisms and Clinical Implications
- (2010) Lynne Strasfeld et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Host-Directed Drug Targeting of Factors Hijacked by Pathogens
- (2008) A. Schwegmann et al. Science Signaling
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started